Abstract
Solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT) recipients are at increased risk for developing infections due to underlying immunosuppression. Antibiotic use, and in HSCT recipients, the use of preparative regimens prior to transplantation can deplete gut commensal bacteria, resulting in intestinal dysbiosis. Emerging evidence in transplant patients, particularly HSCT, suggest that disturbances in gut microbiota populations are associated with a number of adverse outcomes. Here, we review the outcomes of HSCT and SOT recipients with gut microbiota imbalance or dysbiosis, explore the nascent field of gut microbiome therapeutic approaches including fecal microbiota transplantation and the use of precision probiotics in HSCT and SOT recipients.
Original language | English (US) |
---|---|
Article number | 100614 |
Journal | Blood Reviews |
Volume | 39 |
DOIs | |
State | Published - Jan 2020 |
Keywords
- Colonization resistance
- Fecal microbiota transplant
- Gut microbiome
- Microbiota
- Transplant
ASJC Scopus subject areas
- Hematology
- Oncology